{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:42:23Z","timestamp":1760035343080,"version":"build-2065373602"},"reference-count":15,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background: A single measurement or a summary of a limited number of measurements of CA125 was considered in the prediction of clinical outcomes for patients with ovarian cancer. We aimed to identify the classes of patients with advanced ovarian cancer based on their CA125 trajectory and to investigate the heterogeneity of clinical outcomes among the patients in the different classes. Methods: CA125 trajectory classes were identified by latent-class mixed models based on values collected within 3 and 6 months post-treatment for 819 women with advanced ovarian cancer enrolled in a randomized trial. Results: Based on their CA125 values during the first 6 months of treatment, the patients with low CA125 levels at baseline that remained low during treatment had the best clinical outcome (a median survival of 83 months and a progression-free survival of 34 months). In contrast, the patients with high CA125 values at baseline with a modest decrease during treatment had the highest risk of death and progression (hazard ratio [95% confidence interval]: 4.83 [3.56, 6.54] for overall survival and 5.15 [3.87, 6.87] for progression-free survival). Conclusions: Longitudinal trajectories of CA125 may provide more direct information for the prognoses of patients with advanced ovarian cancer undergoing chemotherapy treatment.<\/jats:p>","DOI":"10.3390\/curroncol32070390","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T06:03:13Z","timestamp":1751868193000},"page":"390","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Trajectories of Cancer Antigen 125 (CA125) Within 3 and 6 Months After the Initiation of Chemotherapy Treatment for Advanced Ovarian Cancer and Clinical Outcomes: A Secondary Analysis of Data from a Phase III Clinical Trial"],"prefix":"10.3390","volume":"32","author":[{"given":"Chang","family":"Yin","sequence":"first","affiliation":[{"name":"Department of Biostatistics, School of Public Health, Fudan University, and the Key Laboratory of Public Health Safety of Ministry of Education, Shanghai 200032, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josee-Lyne","family":"Ethier","sequence":"additional","affiliation":[{"name":"Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark S.","family":"Carey","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC V6H 3N1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4842-2184","authenticated-orcid":false,"given":"Dongsheng","family":"Tu","sequence":"additional","affiliation":[{"name":"Canadian Cancer Trials Group, Queen\u2019s University, Kingston, ON K7L 3N6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueying","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, School of Public Health, Fudan University, and the Key Laboratory of Public Health Safety of Ministry of Education, Shanghai 200032, China"},{"name":"Shanghai Institute of Infectious Disease and Biosecurity, Shanghai 200032, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Vaicekauskait\u0117, I., Kazlauskait\u0117, P., Gineikait\u0117, R., \u010ciurlien\u0117, R., Lazutka, J.R., and Sabaliauskait\u0117, R. (2025). Integrative Analysis of Gene Expression and Promoter Methylation to Differentiate High-Grade Serous Ovarian Cancer from Benign Tumors. Biomedicines, 13.","DOI":"10.3390\/biomedicines13020441"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"480.e1","DOI":"10.1016\/j.ajog.2011.06.049","article-title":"Natural history and outcome of mucinous carcinoma of the ovary","volume":"205","author":"Schiavone","year":"2011","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s00404-014-3364-8","article-title":"The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer","volume":"290","author":"Zeppernick","year":"2014","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3802\/jgo.2014.25.1.51","article-title":"A longitudinal analysis with CA-125 to predict overall survival in patients with ovarian cancer","volume":"25","author":"Chiang","year":"2014","journal-title":"J. Gynecol. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Piatek, S., Panek, G., Lewandowski, Z., Piatek, D., Kosinski, P., and Bidzinski, M. (2021). Nadir CA-125 has prognostic value for recurrence, but not for survival in patients with ovarian cancer. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-97564-1"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5342","DOI":"10.1158\/1078-0432.CCR-18-3335","article-title":"Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study","volume":"25","author":"Colomban","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"112966","DOI":"10.1016\/j.ejca.2023.112966","article-title":"Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis","volume":"191","author":"Corbaux","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Karamouza, E., Glasspool, R.M., Kelly, C., Lewsley, L.A., Carty, K., Kristensen, G.B., Ethier, J.L., Kagimura, T., Yanaihara, N., and Cecere, S.C. (2023). CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data. Cancers, 15.","DOI":"10.3390\/cancers15061823"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/jnci\/djq362","article-title":"Advanced ovarian cancer: Phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel","volume":"102","author":"Hoskins","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_10","first-page":"1","article-title":"Estimation of Extended Mixed Models Using Latent Classes and Latent Processes: The R Package lcmm","volume":"78","author":"Lima","year":"2017","journal-title":"J. Stat. Softw."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.20982\/tqmp.05.1.p011","article-title":"Latent Class Growth Modelling: A Tutorial","volume":"5","author":"Andruff","year":"2009","journal-title":"Tutor. Quant. Methods Psychol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.2147\/CLEP.S265287","article-title":"Trajectory Modelling Techniques Useful to Epidemiological Research: A Comparative Narrative Review of Approaches","volume":"12","author":"Katz","year":"2020","journal-title":"Clin. Epidemiol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Li, C., Zhang, D., Pang, X., Pu, H., Lei, M., Fan, B., Lv, J., You, D., Li, Z., and Zhang, T. (2021). Trajectories of Perioperative Serum Tumor Markers and Colorectal Cancer Outcomes: A Retrospective, Multicenter Longitudinal Cohort Study. EBioMedicine, 74.","DOI":"10.1016\/j.ebiom.2021.103706"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"6117","DOI":"10.1002\/cam4.5341","article-title":"Clustering on longitudinal quality-of-life measurements using growth mixture models for clinical prognosis: Implementation on CCTG\/AGITG CO.20 trial","volume":"12","author":"Zhang","year":"2023","journal-title":"Cancer Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1093\/annonc\/mdq770","article-title":"Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: An NCIC CTG OV.16 correlative study","volume":"22","author":"Weberpals","year":"2011","journal-title":"Ann. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/7\/390\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:05:43Z","timestamp":1760033143000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/7\/390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":15,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["curroncol32070390"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32070390","relation":{},"ISSN":["1718-7729"],"issn-type":[{"type":"electronic","value":"1718-7729"}],"subject":[],"published":{"date-parts":[[2025,7,7]]}}}